L-Asparaginase-induced fulminating liver dysfunction

Int J Hematol. 2013 Jul;98(1):6-7. doi: 10.1007/s12185-013-1375-z. Epub 2013 May 24.

Authors

Atsuo Okamura¹, Meiko Nishimura, Yukinari Sanada, Kimikazu Yakushijin, Hiroshi Matsuoka, Katsuya Yamamoto, Hironobu Minami

Affiliation

¹ Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. atsuo@godzilla.kobe-u.ac.jp

PMID: 23702916
DOI: 10.1007/s12185-013-1375-z

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Asparaginase / administration & dosage
Asparaginase / adverse effects*
Asparaginase / therapeutic use
Chemical and Drug Induced Liver Injury / diagnostic imaging
Chemical and Drug Induced Liver Injury / drug therapy
Chemical and Drug Induced Liver Injury / physiopathology*
Cholagogues and Choleretics / therapeutic use
Drug Monitoring
Female
Humans
Induction Chemotherapy / adverse effects
Leukemia, B-Cell / drug therapy
Liver / diagnostic imaging
Liver / drug effects*
Protective Agents / therapeutic use
Radiography
Severity of Illness Index
Treatment Outcome
Ursodeoxycholic Acid / therapeutic use

Substances

Antineoplastic Agents
Cholagogues and Choleretics
Protective Agents
Ursodeoxycholic Acid
Asparaginase